These remain good days for Swiss drug and diagnostics giant Roche (Nasdaq:RHHBY), as the company continues to see double-digit growth across most of its oncology franchise, with ongoing growth in diagnostics and early signs of additional operating leverage. While Roche's oncology pipeline looks solid, it's well worth asking if management has been too slow to move to bulk up other areas. Although Roche shares still look a little undervalued, M&A speculation is likely to remain in play for the foreseeable future, likely adding volatility to the shares.
Good Leverage Leads To Upside In The First Half
Although Roche's top-line results were almost exactly in line with expectations, the company still managed to beat operating assumptions by a meaningful amount due to more effective marketing leverage.
Revenue rose 5% (in constant currency) this quarter, led by 6% growth in the pharma business and 3% growth in the diagnostics business. Within drugs, Avastin and the company's HER2 franchise continue to grow at double-digit rates, while Lucentis was also up by double digits. Within diagnostics, Roche's professional business was up 6% (similar to Abbott (NYSE:ABT)), with double-digit growth in immunoassay. Tissue diagnostics was also pretty good (up 6%), while molecular diagnostics was weak and up only 1%. Roche's negative 5% performance in diabetes was poor, but at least better than Johnson & Johnson (NYSE:JNJ) as the major testing companies suffer through a harsher reimbursement environment.
SEE: Evaluating Pharmaceutical Companies

On the margin side, Roche was already a fairly strong performer. Nevertheless, marketing expense growth of just 3% allowed the company to post 10% growth in operating income (or 7% netting out pension adjustments), with pharma up 8% and diagnostics up 9%. On a margin basis, Roche outperformed the average sell-side target by 120bp.
Forget Alexion, But M&A Makes Sense
As I expected, Roche threw cold water on the notion of buying Alexion (Nasdaq: ALXN), the orphan drug specialist. While Alexion looked like a very expensive deal for Roche, and one with high execution risk and minimal synergies, the notion that Roche should and will do deals is sound.
Over 60% of the company's pharmaceutical sales come from oncology, and Roche has seen some embarrassing trial failures in areas like diabetes and cardiovascular disease in its attempts to diversify. Although there are some interesting and high-potential drugs in the pipeline (including a Glyt-1 inhibitor for schizophrenia, etrolizumab in ulcerative colitis, and crenezeumab in Alzheimer's disease), Roche would likely do well for itself by adding more heft to its non-oncology operations.

The question, though, is one of price. With the multi-year bull market in biotech having spiked valuations, there aren't many bargains left. Still, I could see Roche possibly having some interest in companies like Biogen Idec (Nasdaq: BIIB), Vertex (Nasdaq: VRTX), or other orphan drug companies were valuations to ease off over the next year or two.
An Attractive Pipeline Moving Forward
Roche still has an attractive pipeline of its own. Between Roche management and comments from Bristol-Myers (NYSE: BMY), it sounds as though the timeline for PDL-1 could be shorter, and GA101 looks well-positioned as a follow-on to Rituxan (a drug where biosimilar competition in Europe is starting to look like more of a threat).

SEE: The Value Investor's Handbook
The Bottom Line
Even with the strong performance in these shares over the past year, there still seems to be some value left. With long-term free cash flow growth in the neighborhood of 5%, a fair value in the mid-to-high $60s is reasonable. While Pfizer (NYSE: PFE) may have more upside with respect to current growth expectations, Roche remains one of the more attractive large-cap pharmaceuticals, with relatively limited patent risk and several significant pipeline/launch developments over the next 12 months.
Disclosure – As of this writing, the author owns shares of Roche.

Related Articles
  1. Investing

    The ABCs of Bond ETF Distributions

    How do bond exchange traded fund (ETF) distributions work? It’s a question I get a lot. First, let’s explain what we mean by distributions.
  2. Stock Analysis

    The 5 Best Dividend Stocks in the Healthcare Sector

    Learn about the top five dividend stocks of companies operating in the health care sector that generate substantial cash flows to afford high payouts.
  3. Stock Analysis

    3 Stocks that Are Top Bets for Retirement

    These three stocks are resilient, fundamentally sound and also pay generous dividends.
  4. Investing News

    Are Stocks Cheap Now? Nope. And Here's Why

    Are stocks cheap right now? Be wary of those who are telling you what you want to hear. Here's why.
  5. Investing News

    4 Value Stocks Worth Your Immediate Attention

    Here are four stocks that offer good value and will likely outperform the majority of stocks throughout the broader market over the next several years.
  6. Investing News

    These 3 High-Quality Stocks Are Dividend Royalty

    Here are three resilient, dividend-paying companies that may mitigate some worry in an uncertain investing environment.
  7. Stock Analysis

    An Auto Stock Alternative to Ford and GM

    If you're not sure where Ford and General Motors are going, you might want to look at this auto investment option instead.
  8. Mutual Funds & ETFs

    The 4 Best Buy-and-Hold ETFs

    Explore detailed analyses of the top buy-and-hold exchange traded funds, and learn about their characteristics, statistics and suitability.
  9. Mutual Funds & ETFs

    Top 5 Health Mutual Funds

    Learn about the top five mutual funds that invest in stocks of companies that primarily operate in the health care sector of the United States.
  10. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!